Australia is anticipating the availability of Retatrutide, a novel medication developed by Novo Nordisk. This dual-action drug, targeting both GLP-1 and GIP receptors, has shown significant performance in testing, https://bookmarking1.com/story22013541/novo-nordisk-s-retatrutide-australia-a-potential-advancement-for-weight-management